(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 10.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.96%.
Immunocore Holdings's revenue in 2026 is $430,775,000.On average, 16 Wall Street analysts forecast IMCR's revenue for 2026 to be $23,727,987,783, with the lowest IMCR revenue forecast at $22,232,467,945, and the highest IMCR revenue forecast at $25,312,085,242. On average, 16 Wall Street analysts forecast IMCR's revenue for 2027 to be $25,777,117,753, with the lowest IMCR revenue forecast at $17,446,186,481, and the highest IMCR revenue forecast at $32,493,052,396.
In 2028, IMCR is forecast to generate $30,277,066,907 in revenue, with the lowest revenue forecast at $15,613,865,688 and the highest revenue forecast at $45,719,442,200.